DC Field | Value | Language |
dc.contributor.author | Elagin, V. V. | - |
dc.contributor.author | Bratchikov, O. I. | - |
dc.contributor.author | Zatolokina, M. A. | - |
dc.date.accessioned | 2022-04-25T11:18:19Z | - |
dc.date.available | 2022-04-25T11:18:19Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Elagin, V.V. Correction of morphofunctional disorders with asialoerythropoietin and selective inhibitor of arginase II KUD975 in cases of ischemic kidney damage in the experiment / V.V. Elagin, O.I. Bratchikov, M.A. Zatolokina // Research Results in Pharmacology. - 2018. - Vol. 4, № 4.- P. 29-40. - Doi: 10.3897/rrpharmacology.4.31846. - Refer.: p. 39-40. | ru |
dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46339 | - |
dc.description.abstract | Acute kidney injury (AKI), which is based on ischemic-reperfusion damage, is a widespread life-threatening condition and remains a serious public health problem with a high mortality rate among patients. Pharmacological preconditioning and the use of endothelioprotectors are promising areas in this field, therefore the purpose of this study was to analyze the nephroprotective properties of asialoerythropoietin and selective inhibitor of arginase II KUD975 in ischemic kidney damage in the experiment | ru |
dc.language.iso | en | ru |
dc.subject | medicine | ru |
dc.subject | pharmacology | ru |
dc.subject | acute kidney injury | ru |
dc.subject | ischemic-reperfusion kidney | ru |
dc.subject | endothelial dysfunction | ru |
dc.subject | pharmacological preconditioning | ru |
dc.subject | asialoerythropoietin | ru |
dc.subject | selective inhibitor of arginase | ru |
dc.title | Correction of morphofunctional disorders with asialoerythropoietin and selective inhibitor of arginase II KUD975 in cases of ischemic kidney damage in the experiment | ru |
dc.type | Article | ru |
Appears in Collections: | Vol. 4, № 4
|